CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SIVIDON developed the ChemoPredict test, a diagnostic tool for stratifying high-risk breast cancer patients to optimize chemotherapy treatment. This assay aims to reduce unnecessary taxane-based therapies while maintaining patient outcomes, ultimately enhancing personalized medicine in breast cancer care.
SIVIDON established a prototype diagnostic assay - the ChemoPredict test - to stratify high-risk breast cancer patients and to help in deciding whether to treat the patient with standard anthracycline-based chemotherapy without taxane or taxane-containing regimens.
ChemoPredict was clinically validated in a large clinical phase III trial (FinHer) with 919 patients using a prospective-retrospective approach.
The existing training and validation studies of ChemoPredict provided evidence that the a…
SIVIDON DIAGNOSTICS GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
